Skip to main content

Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review

Medical Oncology volume 35, Article number: 37 (2018) Cite this article

Abstract

Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients present with loco-regionally advanced disease. The rate of second primary tumors after a diagnosis of HNC is about 3–7% per year, the highest rate among solid tumors. Currently, a single-modality or a combination of surgery, radiotherapy and chemotherapy (CHT), is the standard treatment for stage III–IV HNC. For the recurrent/metastatic setting, in the last 40 years great efforts have been made in order to develop a more effective CHT regimen, from the use of methotrexate alone, to the combination of cisplatin (CDDP) and 5-fluorouracile (5FU) or paclitaxel. Recently, the introduction of cetuximab, an anti-EGFR monoclonal antibody, to the CDDP–5FU doublet (EXTREME regimen) has improved the overall response rate, the progression-free survival and the overall survival (OS) compared to CHT alone. Nowadays, the EXTREME regimen is the standard of care for the first-line treatment of recurrent/metastatic head and neck carcinoma (RMHNC). In the last years, new promising therapies for RMHNC such as immune checkpoint inhibitors (ICIs), which have demonstrated favorable results in second-line clinical trials, gained special interest. Nivolumab and pembrolizumab are the first two ICIs able to prolong OS in the second-, later-line and platinum-refractory setting, with tolerable toxicities. This review summarizes the current state of the art in RMHNC treatment options.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.

    Article  PubMed  Google Scholar 

  2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016.

  3. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran pathologic basis of disease. 8th ed. Philadelphia: Saunders Elsevier; 2010.

    Google Scholar 

  4. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359:1143.

    CAS  Article  PubMed  Google Scholar 

  5. Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Cancer. 1992;70:14.

    CAS  Article  PubMed  Google Scholar 

  6. Van Dijk BAC, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, Licitra L. The RARECARE Working Group. Rare cancers of the head and neck area in Europe. Eur J Cancer. 2012;48(6):783–96.

    Article  PubMed  Google Scholar 

  7. Gillison ML, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–20.

    CAS  Article  PubMed  Google Scholar 

  8. Young D, Xiao CC, Murphy B, Moore M, Fakhry C, Day TA. Increase in head and neck cancer in younger patients due to human papillomavirus (HPV). Oral Oncol. 2015;51:727–30.

    Article  PubMed  Google Scholar 

  9. Yen TT, Lin WD, Wang CP, et al. The association of smoking, alcoholic consumption, betel quid chewing and oral cavity cancer: a cohort study. Eur Arch Otorhinolaryngol. 2008;265:1403–7.

    Article  PubMed  Google Scholar 

  10. Slaughter DP, et al. “Field cancerization” in oral stratified squamous epithelium. Cancer. 1953;6:962.

    Article  Google Scholar 

  11. Karatzanis AD, Koudounarakis E, Papadakis I, Velegrakis G. Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer. Eur Arch Otorhinolaryngol. 2012;269:731–7.

    CAS  Article  PubMed  Google Scholar 

  12. Madden RE, Gyur L. Translymphnodal passage of tumor cells. Oncology. 1968;22:281–9.

    CAS  Article  PubMed  Google Scholar 

  13. Fisher B, Fisher ER. Transmigration of lymph nodes by tumor cells. Science. 1966;152:1397–8.

    CAS  Article  PubMed  Google Scholar 

  14. Allen CT, Law JH, Dunn GP, Uppaluri R. Emerging insights into head and neck cancer metastasis. Head Neck. 2013;35(11):1669–78.

    Article  PubMed  Google Scholar 

  15. Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–60.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Cohen S. Origins of growth factors: NGF and EGF. Ann N Y Acad Sci. 2004;1038:98–102.

    Article  PubMed  Google Scholar 

  17. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666–72.

    CAS  Article  PubMed  Google Scholar 

  18. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factors alpha and epidermal growth factor receptor messenger RNA are early markers in carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579–84.

    CAS  PubMed  Google Scholar 

  19. Taylor SG IV, McGuire WP, Hauck WW, Showel JL, Lad TE. A randomized comparison of high dose methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J Clin Oncol. 1984;2(9):1006–11.

    Article  PubMed  Google Scholar 

  20. Woods RL, Fox RM, Tattersall MH. Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation. Br Med J (Clin Res Ed). 1981;282(6264):600–2.

    CAS  Article  Google Scholar 

  21. Pitman SW, Miller D, Weichselbaum R. Initial adjuvant therapy in advanced squamous-cell carcinoma of the head and neck employing weekly high dose methotrexate with leucovorin rescue. Laryngoscope. 1978;88(4):632–8.

    CAS  Article  PubMed  Google Scholar 

  22. Carter SK, Slavik M. Current investigational drugs of interest in the chemotherapy program of the National Cancer Institute. Natl Cancer Inst Monogr. 1977;45:101–21.

    Google Scholar 

  23. Wittes RE. Chemotherapy of head and neck cancer. Otolaryngol Clin North Am. 1980;13:515–20.

    CAS  PubMed  Google Scholar 

  24. Eisemberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D. Carboplatin (NSC-241.240): an active platinum analogue for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1986;4:1506–9.

    Article  Google Scholar 

  25. Wittes RE, Cvitkovic E, Shah J, Gerold FP, Strong EW. CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of head and neck. Cancer Treat Rep. 1977;61(3):359–66.

    CAS  PubMed  Google Scholar 

  26. Wittes R, Heller K, Randolph V, Howard J, Vallejo A, Farr H, et al. Cis-Dichlorodiammineplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep. 1979;63(9–10):1533–8.

    CAS  PubMed  Google Scholar 

  27. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous-cell carcinoma of the head and neck region: a Southwest Oncology Group Study. Cancer Treat Rep. 1985;69(6):577–81.

    CAS  PubMed  Google Scholar 

  28. Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, Cormick MC, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15(3):283–9.

    CAS  Article  PubMed  Google Scholar 

  29. Liverpool Head and Neck Oncology Group. A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatin + 5-FU in end stage squamous carcinoma of head and neck. Br J Cancer. 1990;62(1):171.

    Article  Google Scholar 

  30. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus 5fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group Study. J Clin Oncol. 1992;10(8):1245–51.

    CAS  Article  PubMed  Google Scholar 

  31. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257–63.

    CAS  Article  PubMed  Google Scholar 

  32. Clacel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous-cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521–6.

    Article  Google Scholar 

  33. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al. Docetaxel (Taxotere). An active drug for the treatment of patients with advanced squamous-cell carcinoma of the head and neck—EORTC Early Clinical Trials Group. Ann Oncol. 1994;5:233–7.

    Article  Google Scholar 

  34. Al Dreyfuss, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: an active drug for squamous-cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672–8.

    Article  Google Scholar 

  35. Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol. 2005;17:218–24.

    CAS  Article  PubMed  Google Scholar 

  36. Forastiere AA, Shank D, Neuberg D, Taylor SG 4th, DeConti RG, Adams G. Final report of a phase II evaluation of paclitaxel in squamous-cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer. 1998;82:2270–4.

    CAS  Article  PubMed  Google Scholar 

  37. Smith RE, Thornoton DE, Allen J. A phase II trial of paclitaxel in squamous-cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol. 1995;22:41–6.

    CAS  PubMed  Google Scholar 

  38. Gibson MK, Li Y, Murphy B, Hussain MH, De Conti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562–7.

    CAS  Article  PubMed  Google Scholar 

  39. Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Oncology Group Study E1393. J Clin Oncol. 2001;19(4):1088–95.

    CAS  Article  PubMed  Google Scholar 

  40. Ferrari D, Fiore J, Codecà C, Di Maria G, Bozzoni S, Bordin V, et al. A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. Anticancer Drugs. 2009;20(3):185–9.

    CAS  Article  PubMed  Google Scholar 

  41. Soulieres D, Faivre S, Mesia R, Remenar E, Li SH, Karpenko A, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous-cell carcinoma of the head and neck (BERIL-1): a randomized, double-blind, placebo-controlled phase II trial. Lancet Oncol. 2017;18(3):323–35.

    CAS  Article  PubMed  Google Scholar 

  42. Lay J, Wildes TM, Daly K, Oppelt P, Adkins D. Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous-cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. Med Oncol. 2017;34:28.

    Article  Google Scholar 

  43. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open label trial. Lancet. 2010;376(9747):1147–54.

    Article  PubMed  Google Scholar 

  44. Machielis JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry S, et al. Randomized phase II study of Cabazitaxel versus Methotrexate in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck previously treated with platinum-based therapy. Oncologist. 2016;21(12):1416–7.

    Article  Google Scholar 

  45. Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, et al. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase III study. Cancer. 2012;118(19):4694–705.

    CAS  Article  PubMed  Google Scholar 

  46. Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001;91(7):1316–23.

    CAS  Article  PubMed  Google Scholar 

  47. Shin DM, Gibson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, et al. Phase II study of paclitaxel, ifosfamide and cisplatin in patients with recurrent head and neck squamous-cell carcinoma. J Clin Oncol. 1998;16:1325–30.

    CAS  Article  PubMed  Google Scholar 

  48. Li S, Schmitz KR, Jeffrey PD, Wiltzius PD, Kussie P, Ferguson KM. Structural basis for the inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301–11.

    CAS  Article  PubMed  Google Scholar 

  49. Taylor RJ, Chan SL, Wood A. FcγRIII polymorphism and cetuximab induced cytoxicity in squamous-cell carcinoma of the head and neck. Cancer Immunol Immunother. 2009;58:997–1006.

    CAS  Article  PubMed  Google Scholar 

  50. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as single agent in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–7.

    CAS  Article  PubMed  Google Scholar 

  51. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646–54.

    Article  PubMed  Google Scholar 

  52. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecky A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck canecer. N Engl J Med. 2008;359:1116–27.

    CAS  Article  PubMed  Google Scholar 

  53. Nakano K, Marshall S, Taira S, et al. A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma. Oral Oncol. 2017;73:21–6.

    CAS  Article  PubMed  Google Scholar 

  54. Bossi P, Miceli R, Locati LD, et al. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2017;28(11):2820–6.

    CAS  Article  PubMed  Google Scholar 

  55. Peeters M, Cohn A, Kohne CH, Douillard JY. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. Clin Colorectal Cancer. 2012;11:14–23.

    CAS  Article  PubMed  Google Scholar 

  56. Vermorken JB, Stohlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase III randomized trial. Lancet Oncol. 2013;14(8):697–710.

    CAS  Article  PubMed  Google Scholar 

  57. Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, et al. PARTNER: an open-label, phase II study of docetaxel/cisplatin with or without Panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2016;61:31–40.

    CAS  Article  PubMed  Google Scholar 

  58. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24(1):220–5.

    CAS  Article  PubMed  Google Scholar 

  59. Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2001;29(9):1140–5.

    Article  Google Scholar 

  60. Cohen EE, Rosen F, Stadle WM, Recant W, Stenson K, Huo D, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous-cell carcinoma of the head and neck. J Clin Oncol. 2003;21(10):1980–7.

    CAS  Article  PubMed  Google Scholar 

  61. Cohen EE, Kane MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Clin Cancer Res. 2005;11(23):8418–24.

    CAS  Article  PubMed  Google Scholar 

  62. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous-cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27(11):1864–71.

    CAS  Article  PubMed  Google Scholar 

  63. Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2013;31(11):1405–14.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  64. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous-cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77–85.

    CAS  Article  PubMed  Google Scholar 

  65. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I–II study. Lancet Oncol. 2009;10(3):247–57.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  66. Seiwert T, Fayette J, Cupissol D, DelCampo JM, Clement PM, Hitt R, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014;25(9):1813–20.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  67. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX Head and Neck 1): an open-label, randomized phase III trial. Lancet Oncol. 2015;16(5):583–94.

    CAS  Article  PubMed  Google Scholar 

  68. Cohen EE, LaMonte SJ, Erb NL, et al. American cancer society head and neck cancer survivorship care guideline. CA Cancer J Clin. 2016;66(3):203–39.

    Article  PubMed  Google Scholar 

  69. Epstein JB, Thariat J, Bensadoun R-J, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400–22.

    Article  PubMed  Google Scholar 

  70. Dorsey K, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs. 2013;73(4):315–25.

    CAS  Article  PubMed  Google Scholar 

  71. Pai SI, Zandberg DP, Strome SE. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncol. 2016;61:152–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  72. Pai SI. Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. Oncoimmunology. 2013;2(5):e24065.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143–53.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  74. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  75. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270–1.

    Article  PubMed  Google Scholar 

  76. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–17.

    CAS  Article  PubMed  Google Scholar 

  78. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  79. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17:943–55.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  80. Robert C, Soria JC, Eggermont AM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer. 2013;49:2968–71.

    CAS  Article  PubMed  Google Scholar 

  81. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65.

    CAS  Article  PubMed  Google Scholar 

  82. Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838–45.

    CAS  Article  PubMed  Google Scholar 

  83. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–78.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  85. Zhang X, Schwartz JC, Guo X, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004;20(3):337–47.

    CAS  Article  PubMed  Google Scholar 

  86. Cheng X, Veverka V, Radhakrishnan A, et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem. 2013;288(17):11771–85.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  87. Yao Q, Fischer KP, Tyrrell DL, Gutfreund KS. The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis. Int J Immunogenet. 2015;42(2):111–20.

    CAS  Article  PubMed  Google Scholar 

  88. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733–41.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  89. Yu GT, Bu LL, Huang CF, et al. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma. Oncotarget. 2015;6(39):42067–80.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–77.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  91. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355–63.

    CAS  Article  PubMed  Google Scholar 

  92. Concha-Benavente F, Srivastava RM, Trivedi S, et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer. Cancer Res. 2016;76(5):1031–43.

    CAS  Article  PubMed  Google Scholar 

  93. Straub M, Drecoll E, Pfarr N, et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget. 2016;7(11):12024–34.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Ibrahim R, Stewart R, Shalabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol. 2015;42(3):474–83.

    CAS  Article  PubMed  Google Scholar 

  95. Bauml J. Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2016: ASCO meeting abstracts:34(Suppl):abstr 6011.

  96. Harrington KJ, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18(8):1104–15.

    CAS  Article  PubMed  Google Scholar 

  97. Segal NH. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol. 2015:ASCO meeting abstracts:33(Suppl):abstr 3011.

  98. Fury M, Ou SI, Balmanoukian A, et al. Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, in patients with head and neck cancer. Ann Oncol. 2014;25(Suppl 4):iv341.

    Article  Google Scholar 

  99. Jie HB, Srivastava RM, Argiris A, et al. Increased PD-1 + and TIM-3 + TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients. Cancer Immunol Res. 2017;5(5):408–16.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medical Oncology, San Paolo Hospital, Via Antonio di Rudinì, 8, 20142, Milan, Italy

    Alessandro Guidi, Carla Codecà & Daris Ferrari

Authors
  1. Alessandro Guidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carla Codecà
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daris Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandro Guidi.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Guidi, A., Codecà, C. & Ferrari, D. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol 35, 37 (2018). https://doi.org/10.1007/s12032-018-1096-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-018-1096-5

Keywords

  • Immunotherapy
  • Chemotherapy
  • Monoclonal antibodies
  • Recurrent/metastatic head and neck cancer